SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results